CClinicalTrials.gg
Status unknownNCT04339361Updated Apr 9, 2020

Comparative Efficacy of Lidocaine Spray Versus Vaginal Dinoprostone in IUD Insertion

A Phase 4 interventional study of lidocaine spray and vaginal dinoprostone in Contraception, sponsored by Cairo University. Status unknown. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-09.

Sponsored by Cairo University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
111
Allocation
Randomized
Sex
Female
01

Study summary

the aim of this study is to compare the safety and Efficacy of Lidocaine Spray Versus Vaginal dinoprostone in relieving pain during levonorgestrel IUD Insertion in nulliparous women

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • nulliparous women requesting levonorgestrel IUD insertion

Exclusion criteria

Exclusion Criteria:

  • multiparous women, allergy or contraindication to study drugs or contraindications to LNG-IUD insertion
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (estimated)

Study arms

  • Experimental
    lidocaine spray

    four puffs (50ml, 10 mg/puff) of lidocaine spray will be applied to the cervical canal and cervix before tenaculum placement plus vaginal placebo will be given 3 hours before IUD insertion

    Drug: lidocaine spray

  • Active comparator
    vaginal dinoprostone

    vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement

    Drug: vaginal dinoprostone

  • Placebo comparator
    placebo

    vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement

    Drug: placebo

Interventions

  • Druglidocaine spray

    four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion

  • Drugvaginal dinoprostone

    vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement

  • Drugplacebo

    vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement

06

What researchers measure

Primary outcomes

  1. pain during IUD insertion

    pain during IUD insertion assessed by 10 cm visual analog scale where 0 denotes no pain and 10 denotes the worst pain imaginable

    Time frame: 2 minutes

Secondary outcomes

  1. insertion duration

    duration of LNG-IUD insertion from speculum in to speculum out

    Time frame: 5 minutes

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04339361
Lead sponsor
Cairo University
Responsible party
Ahmed Samy aly ashour (assistant professor obstetrics and gynecology, Cairo University) — Principal investigator
First posted
Apr 9, 2020
Start date
Apr 25, 2020 (estimated)
Primary completion
Aug 10, 2020 (estimated)
Completion
Aug 15, 2020 (estimated)
Last update
Apr 9, 2020

Study contacts

AHMED SAMY
Contact
ahmedsamy8233@gmail.com
+201100681167

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion